Maxalt

Rizatriptan, the active ingredient in Maxalt, is a triptan presented as a tablet for oral use. It is indicated for the acute treatment of migraine attacks with or without aura in adult patients.

GNH USA supplies Maxalt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maxalt belongs to the triptan class and is used for acute migraine management.

Migraine with aura: provides rapid relief of headache and associated symptoms. Migraine without aura: reduces pain intensity and duration of an attack. Acute migraine attacks: aborts migraine episodes when taken at the first sign of headache.

Rizatriptan may cause a range of adverse reactions.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or face - Dizziness or light‑headedness - Nausea or abdominal pain - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm leading to chest pain or myocardial ischemia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions such as anaphylaxis or angioedema - Cardiac arrhythmias or hypertension - Persistent visual disturbances - Severe abdominal pain or gastrointestinal bleeding

Before prescribing Maxalt, clinicians should consider several safety factors. - Cardiovascular assessment: avoid in patients with uncontrolled coronary artery disease or recent myocardial infarction. - Concomitant serotonergic drugs: assess risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAO inhibitors. - Pregnancy: use only if potential benefit justifies potential risk to the fetus. - Age: safety and efficacy have not been established in children under 18 years. - Drug interactions: review all concomitant medications for possible interactions. - Store at ambient temperature: keep below 25°C, protect from moisture and light in the original packaging.

Rizatriptan can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - MAO inhibitors: increased risk of serotonin syndrome. - Ergot alkaloids: additive vasoconstriction may cause severe cardiovascular events. - Other triptans: combined use can lead to excessive vasoconstriction.

Moderate Interactions (Monitor Closely): - SSRIs, SNRIs, or other serotonergic agents: monitor for signs of serotonin syndrome. - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effectiveness.